ABIVAX Société Anonyme - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABVX Nasdaq 2836 www.abivax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABIVAX Société Anonyme

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment - Jan 9th, 2025 4:35 pm
Abivax Announces a Change to the Composition of its Board of Directors - Dec 23rd, 2024 9:05 pm
Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now? - Dec 4th, 2024 9:42 pm
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - Nov 19th, 2024 9:30 pm
Abivax presents third quarter 2024 key financial information - Nov 14th, 2024 9:01 pm
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - Nov 13th, 2024 9:01 pm
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - Oct 7th, 2024 8:01 pm
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease - Oct 3rd, 2024 8:01 pm
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - Oct 3rd, 2024 6:31 am
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - Sep 26th, 2024 6:30 am
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model - Sep 25th, 2024 8:01 pm
Abivax presents first-half 2024 financial results - Sep 9th, 2024 8:01 pm
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone - Aug 6th, 2024 6:30 am
Abivax Provides Operational and Key Program Update - Jul 15th, 2024 8:00 pm
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting - Jun 4th, 2024 8:10 pm
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO) - Feb 13th, 2024 7:50 am